Cytokine receptor zalpha11

An isolated polynucleotide comprising a sequence of polynucleotides that is selected from the group consisting of:

• (a) a polynucleotide sequence as shown in SEQ ID NO:4 from nucleotide 1 to nucleotide 1614;
• (b) a polynucleotide sequence as shown in SEQ ID NO:
• 1 from nucleotide 126 to nucleotide 779;
• (c) a polynucleotide sequence as shown in SEQ ID NO:
• 1 from nucleotide 126 to nucleotide 833;
• (d) a polynucleotide sequence as shown in SEQ ID NO:
• 1 from nucleotide 834 to nucleotide 1682;
• (e) a polynucleotide sequence as shown in SEQ ID NO:
• 1 from nucleotide 126 to nucleotide 1682;
• and
• (f) a polynucleotide sequence as shown in SEQ ID NO:
• 1 from nucleotide 69 to nucleotide 1682.

An expression vector comprising the following operably linked elements:

• a transcription promoter;
• a DNA segment encoding a zalphal I polypeptide having an amino acid sequence as shown in SEQ ID NO:2 from amino acid number 20 (Cys), to amino acid number 538 (Ser);
• and
• a transcription terminator,
• wherein the promoter is operably linked to the DNA segment, and the DNA segment is operably linked to the transcription terminator.

An expression vector comprising:

• a transcription promoter;
• a DNA segment encoding a zalpha11 polypeptide having an amino acid sequence as shown in SEQ ID NO:2 from amino acid number 20 (Cys), to amino acid number 237 (His);
• and
• a transcription terminator,
• wherein the promoter, DNA segment, and terminator are operably linked.

A DNA construct encoding a fusion protein, the DNA construct comprising:

• a first DNA segment encoding a polypeptide having a sequence of amino acid residues selected from the group consisting of:
• (a) the amino acid sequence of SEQ ID NO:2 from amino acid number 1 (Met), to amino acid number 19 (Gly);
• (b) the amino acid sequence of SEQ ID NO:2 from amino acid number 20 (Cys) to amino acid number 237 (His);
• (c) the amino acid sequence of SEQ ID NO:2 from amino acid number 20 (Cys) to amino acid number 255 (Leu);
• (d) the amino acid sequence of SEQ ID NO:2 from amino acid number 238 (Leu) to amino acid number 255 (Leu);
• (e) the amino acid sequence of SEQ ID NO:2 from amino acid number 238 (Leu) to amino acid number 538 (Ser);
• (f) the amino acid sequence of SEQ ID NO:2 from amino acid number 256 (Lys) to amino acid number 538 (Ser);
• and
• (g) the amino acid sequence of SEQ ID NO:2 from amino acid number 20 (Cys), to amino acid number 538 (Ser);
• and
• at least one other DNA segment encoding an additional polypeptide,
• wherein the first and other DNA segments are connected in-frame;
• and
• wherein the first and other DNA segments encode the fusion protein.

An isolated polypeptide comprising a sequence of amino acid residues that is at least 90% identical to an amino acid sequence selected from the group consisting of:

• (a) the amino acid sequence as shown in SEQ ID NO:2 from amino acid number 20 (Cys), to amino acid number 237 (His);
• (b) the amino acid sequence as shown in SEQ ID NO:2 from amino acid number 20 (Cys), to amino acid number 255 (Leu);
• (c) the amino acid sequence as shown in SEQ ID NO:2 from amino acid number 256 (Lys), to amino acid number 538 (Ser);
• (d) the amino acid sequence as shown in SEQ ID NO:2 from amino acid number 20 (Cys), to amino acid number 538 (Ser);
• and
• (e) the amino acid sequence as shown in SEQ ID NO:2 from amino acid number 1 (Met) to amino acid number 538 (Ser),
• wherein the amino acid percent identity is determined using a FASTA program with ktup=1, gap opening penalty=10, gap extension penalty=1, and substitution matrix=BLOSUM62, with other parameters set as default.

A method of producing an antibody to zalpha11 polypeptide comprising:

• inoculating an animal with a polypeptide selected from the group consisting of:
• (a) a polypeptide consisting of 9 to 519 amino acids, wherein the polypeptide consists of a contiguous sequence of amino acids in SEQ ID NO:2 from amino acid number 20 (Cys), to amino acid number 538 (Ser);
• (b) a polypeptide consisting of the amino acid sequence of SEQ ID NO:2 from amino acid number 20 (Cys), to amino acid number 237 (His);
• (c) a polypeptide consisting of the amino acid sequence of SEQ ID NO:2 from amino acid number 101 (Leu) to amino acid number 122 (Gly);
• (d) a polypeptide consisting of the amino acid sequence of SEQ ID NO:2 from amino acid number 141 (Asn) to amino acid number 174 (Ala);
• (e) a polypeptide consisting of the amino acid sequence of SEQ ID NO:2 from amino acid number 193 (Cys) to amino acid number 261 (Val);
• (f) a polypeptide consisting of the amino acid sequence of SEQ ID NO:2 from amino acid number 51 (Trp) to amino acid number 61 (Glu);
• (g) a polypeptide consisting of the amino acid sequence of SEQ ID NO:2 from amino acid 136 (Ile) to amino acid number 143 (Glu);
• (h) a polypeptide consisting of the amino acid sequence of SEQ ID NO:2 from amino acid 187 (Pro) to amino acid number 195 (Ser);
• (i) a polypeptide consisting of the amino acid sequence of SEQ ID NO:2 from amino acid number 223 (Phe) to amino acid number 232 (Glu);
• and
• (j) a polypeptide consisting of the amino acid sequence of SEQ ID NO:2 from amino acid number 360 (Glu) to amino acid number 368 (Asp);
• and
• wherein the polypeptide elicits an immune response in the animal to produce the antibody;
• and
• isolating the antibody from the animal.